drugset
drugset / Trial / NCT06527300

A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer

NCT06527300 ↗

Phase 2 Recruiting 48 enrolled Zhejiang Wenda Pharma Technology LTD.
NaSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.

Timeline

Start
2024-04-25
Primary completion
2025-06-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NHWD-870 Unknown 1.5 mg Oral
Subject NHWD-870 Unknown 2 mg Oral

Indications

No indication recorded.